BG
INBX

Bellevue Group’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Bellevue Group’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,600
Closed -$935K – 183
2023
Q4 		$935K Sell
24,600
-24,200
-50% -$519K 0.01% 124
2023
Q3 		$895K Hold
48,800
– – 0.01% 130
2023
Q2 		$1.27M Buy
48,800
+19,100
+64% +$446K 0.02% 122
2023
Q1 		$560K Hold
29,700
– – 0.01% 140
2022
Q4 		$732K Sell
29,700
-13,800
-32% -$406K 0.01% 144
2022
Q3 		$781K Sell
43,500
-33,100
-43% -$597K 0.01% 141
2022
Q2 		$869K Buy
76,600
+26,900
+54% +$396K 0.01% 139
2022
Q1 		$1.11M Sell
49,700
-800
-2% -$20.4K 0.01% 147
2021
Q4 		$2.21M Buy
+50,500
New +$2.02M 0.02% 144

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Bellevue Group's INBX Position: Q1 2024 in Review

Bellevue Group sold out of Inhibrx, Inc. Common Stock (INBX) in Q1 2024, closing a stake of 24,600 shares — an estimated $935K sold.

Bellevue Group first reported a position in INBX in Q4 2021 and held it in 9 quarters. The position peaked at $2.21M in Q4 2021. 126 funds tracked by Wall St. Rank hold INBX as of Q1 2024.

  • Bellevue Group reported no remaining Inhibrx, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Bellevue Group sold 24,600 Inhibrx, Inc. Common Stock shares in Q1 2024, an estimated $935K.
  • Bellevue Group first reported a position in Inhibrx, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Bellevue Group's Inhibrx, Inc. Common Stock position peaked at $2.21M in Q4 2021.
  • 126 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q1 2024.

Based on Bellevue Group's 13F filing for Q1 2024, filed 15 May 2024.